News & Analysis on Clinical Trial Services & Contract Research And Development
Sangamo BioSciences has initiated a Phase I clinical trial for its novel therapy for diabetic neuropathy that is designed to protect and stimulate the regeneration of peripheral nerve function in diabetics suffering from peripheral neuropathy.
US researchers think they have found promising new molecular targets and treatment approaches for malignant brain tumours, suggesting a new therapy for anti-cancer drugs.
A new laboratory technique used by fruit fly geneticists for more than a decade is now available to scientists studying genes and diseases in mice. This technique offers a powerful new tool to study genetics, particularly in disease.
A new way of ensuring that pharmaceutical production lines are free of cleaning agents has been developed by Smiths Detection and Dober Group, reports Phil Taylor.
The sudden departure of Merck & Co's chairman and chief executive, Raymond Gilmartin, last week brings into sharp perspective the difficulties facing the ailing US drugmaker, reports Phil Taylor.
Italy's fine chemicals industry organisation, Afaquim, is organising a conference in September aimed at coordinating the efforts of European active pharmaceutical ingredient (API) suppliers in the face of increasing competition from the Far East.
A patent has been issued to Arena Pharmaceuticals for its small molecule treatment for obesity, which targets a specific receptor, thought to be involved in the regulation of food intake and may be useful in pharmaceutical compositions for the...
Arrayjet launches a new inkjet microarray spotter, which uses a modern, replaceable inkjet print head with over 100 nozzles to deliver samples to the array surface. The non-contact technology also has a unique replaceable inject print head for...
Roquette has introduced pyrogen-free versions of its sodium lactate and sodium gluconate products for applications in the pharmaceuticals industry, reports Phil Taylor.
Latin America shows considerable and untapped business potential for the pharmaceutical industry, according to new research conducted by PricewaterhouseCoopers.